WO2006000753A3 - Use of flj40787, a protein involved in colon, colorectal, ovarian, lung and/or liver cancer - Google Patents

Use of flj40787, a protein involved in colon, colorectal, ovarian, lung and/or liver cancer Download PDF

Info

Publication number
WO2006000753A3
WO2006000753A3 PCT/GB2005/002389 GB2005002389W WO2006000753A3 WO 2006000753 A3 WO2006000753 A3 WO 2006000753A3 GB 2005002389 W GB2005002389 W GB 2005002389W WO 2006000753 A3 WO2006000753 A3 WO 2006000753A3
Authority
WO
WIPO (PCT)
Prior art keywords
flj40787
cancer
colorectal
colon
ovarian
Prior art date
Application number
PCT/GB2005/002389
Other languages
French (fr)
Other versions
WO2006000753A2 (en
Inventor
Alasdair Stamps
Original Assignee
Celltech R&D Ltd
Alasdair Stamps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R&D Ltd, Alasdair Stamps filed Critical Celltech R&D Ltd
Publication of WO2006000753A2 publication Critical patent/WO2006000753A2/en
Publication of WO2006000753A3 publication Critical patent/WO2006000753A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

The present invention relates to new uses of FLJ40787 in the diagnosis, screening, treatment and prophylaxis of colon cancer, colorectal cancer, ovarian cancer, lung cancer and/or liver cancer cancer. The invention also provides compositions comprising FLJ40787, including vaccines, antibodies that are immunospecific for FLJ40787 and agents which interact with or modulate the expression or activity of FLJ40787 or which modulate the expression of the nucleic acid which codes for FLJ40787.
PCT/GB2005/002389 2004-06-25 2005-06-17 Use of flj40787, a protein involved in colon, colorectal, ovarian, lung and/or liver cancer WO2006000753A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0414325.1 2004-06-25
GBGB0414325.1A GB0414325D0 (en) 2004-06-25 2004-06-25 A protein involved in cancer

Publications (2)

Publication Number Publication Date
WO2006000753A2 WO2006000753A2 (en) 2006-01-05
WO2006000753A3 true WO2006000753A3 (en) 2006-04-06

Family

ID=32800233

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/002389 WO2006000753A2 (en) 2004-06-25 2005-06-17 Use of flj40787, a protein involved in colon, colorectal, ovarian, lung and/or liver cancer

Country Status (2)

Country Link
GB (1) GB0414325D0 (en)
WO (1) WO2006000753A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1900824A1 (en) * 2006-09-14 2008-03-19 Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts Gene expression signature for the prognosis, diagnosis and therapy of prostate cancer and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001029221A2 (en) * 1999-10-20 2001-04-26 Zymogenetics, Inc. Proteins and polynucleotides encoding them
WO2002016388A1 (en) * 2000-08-18 2002-02-28 Human Genome Sciences, Inc. 21 human secreted proteins
WO2002063006A2 (en) * 2001-02-06 2002-08-15 Incyte Genomics, Inc. Receptors and membrane-associated proteins
WO2004028479A2 (en) * 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis
WO2004043397A2 (en) * 2002-11-12 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of rheumatoid arthritis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001029221A2 (en) * 1999-10-20 2001-04-26 Zymogenetics, Inc. Proteins and polynucleotides encoding them
WO2002016388A1 (en) * 2000-08-18 2002-02-28 Human Genome Sciences, Inc. 21 human secreted proteins
WO2002063006A2 (en) * 2001-02-06 2002-08-15 Incyte Genomics, Inc. Receptors and membrane-associated proteins
WO2004028479A2 (en) * 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis
WO2004043397A2 (en) * 2002-11-12 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of rheumatoid arthritis

Also Published As

Publication number Publication date
GB0414325D0 (en) 2004-07-28
WO2006000753A2 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
IL244803A0 (en) Humanized anti-beta7 antibodies and uses therefore
TW200709817A (en) Platform antibody compositions
IL214325A (en) Anti-cmet antibody, composition comprising it and use thereof
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
WO2007005874A3 (en) Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
HK1103746A1 (en) Antibodies to erythropoietin receptor and uses thereof
TW200732349A (en) Anti-OX40L antibodies and methods using same
WO2008121615A3 (en) Antibody formulation
HK1116803A1 (en) Novel anti-plgf antibody
WO2007067991A3 (en) Human monoclonal antibodies to o8e
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
MY163480A (en) Sclerostin binding agents
WO2007059430A3 (en) Moesin, caveolin 1 and yes associated protein 1 as predictive markers of response to dasatinib in breast cancers
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
EP1742654A4 (en) Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
WO2008049990A3 (en) Use of an anti-cd151 antibody in the treatment of cancer
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use
WO2009049966A3 (en) Methods and tools for prognosis of cancer in her2+ patients
GB0324656D0 (en) A protein involved in ovarian cancer
WO2003087840A3 (en) Protein involved in cancer
WO2006000753A3 (en) Use of flj40787, a protein involved in colon, colorectal, ovarian, lung and/or liver cancer
WO2006123122A3 (en) Psk- i and its modulators for the treatment/diagnosis of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 05755790

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 05755790

Country of ref document: EP

Kind code of ref document: A2